Canada markets close in 1 minute
  • S&P/TSX

    21,082.72
    +97.35 (+0.46%)
     
  • S&P 500

    4,518.95
    +32.49 (+0.72%)
     
  • DOW

    35,453.66
    +195.05 (+0.55%)
     
  • CAD/USD

    0.8087
    +0.0007 (+0.08%)
     
  • CRUDE OIL

    82.88
    +0.44 (+0.53%)
     
  • BTC-CAD

    79,295.90
    +2,924.05 (+3.83%)
     
  • CMC Crypto 200

    1,479.91
    +16.55 (+1.13%)
     
  • GOLD FUTURES

    1,770.00
    +4.30 (+0.24%)
     
  • RUSSELL 2000

    2,272.90
    +5.06 (+0.22%)
     
  • 10-Yr Bond

    1.6350
    +0.0510 (+3.22%)
     
  • NASDAQ

    15,125.55
    +103.74 (+0.69%)
     
  • VOLATILITY

    15.79
    -0.52 (-3.19%)
     
  • FTSE

    7,217.53
    +13.70 (+0.19%)
     
  • NIKKEI 225

    29,215.52
    +190.06 (+0.65%)
     
  • CAD/EUR

    0.6947
    -0.0008 (-0.12%)
     

ZY ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2021 in the Class Action Filed on Behalf of Zymergen Inc. Limited Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - September 28, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Zymergen Inc. (NASDAQ: ZY) alleging that the Company violated federal securities laws.

This lawsuit is on behalf of investors who purchased ZY common stock pursuant and/or traceable to the documents issued in connection with the Company's April 2021 initial public offering.
Lead Plaintiff Deadline: October 4, 2021
No obligation or cost to you.

Learn more about your recoverable losses in ZY:
https://www.kleinstocklaw.com/pslra-1/zymergen-inc-loss-submission-form?id=19931&from=5.

Zymergen Inc. NEWS - ZY NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Zymergen Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) during the qualification process for the Company's optical film product, Hyaline, key customers had encountered technical issues, including product shrinkage and incompatibility with customers' processes; (2) though the qualification process was critical to achieving market acceptance for Hyaline and generating revenue, Zymergen lacked visibility into the qualification process; (3) as a result, the Company overestimated demand for its products; (4) as a result of the foregoing, the Company's product delivery timeline was reasonably likely to be delayed, which in turn would delay revenue generation; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Zymergen you have until October 4, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Zymergen securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the ZY lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97899.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting